Drug Profile
Finafloxacin/AL 817
Alternative Names: AL-60371/AL-817; AL-817/AL-60371; AL-817/finafloxacinLatest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Otitis media
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 19 Apr 2016 No recent reports on development identified - Phase-II for Otitis media in USA (Otic)
- 01 Aug 2014 Alcon terminates phase II trial in Otitis media in USA, due to a management decision (NCT01908803)